Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

28.6%

6 terminated out of 21 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results67% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (6)
P 1 (9)
P 2 (6)

Trial Status

Completed12
Terminated6
Withdrawn2
Recruiting1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT01473784Not ApplicableRecruiting

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

NCT02177838Not ApplicableTerminated

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

NCT01192815Phase 2Terminated

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01469429Phase 1Completed

Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.

NCT02123511Phase 2Completed

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

NCT02048020Phase 2Completed

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

NCT01164566Not ApplicableTerminated

Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01528137Phase 1Terminated

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01334177Phase 1Completed

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

NCT01254734Not ApplicableTerminated

Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

NCT00101348Phase 1Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

NCT00049283Phase 1Completed

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00492089Phase 2Completed

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00513435Phase 2Completed

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01728480Phase 1Withdrawn

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

NCT00906360Phase 1Terminated

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT01155609Not ApplicableCompleted

L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer

NCT01674374Phase 2Withdrawn

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

NCT00089362Phase 1Completed

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00023959Phase 1Completed

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Scroll to load more

Research Network

Activity Timeline